Msac application 1173

Safety

 Toxic effects from subsequent treatment (including skin rash, diarrhoea, thrombocytopenia)

 Adverse events associated with biopsies

 Rate of re-biopsy

Summary of PICO to be used for assessment of evidence (systematic review)

Table 3 provides a summary of the PICO used to: (1) define the question for public funding,

_{(2) select the evidence to assess the safety and effectiveness of EGFR gene mutation}

testing, with erlotinib and

(3) provide the evidence-based inputs for any decision-analysis modelling to determine the cost-effectiveness of EGFR gene mutation testing with erlotinib.
Table 3: Summary of PICO to define the question for public funding that assessment will investigate